"No amounts owed if the clinical trials do not meet the primary endpoint..." That is the line management sold to shareholders.
Basically DFA was if OPT gets to commericalize they get 4X otherwise 0, zero, nill,, sounded like a good deal to the DFA.
Reality: it's 180 degrees different. If it doesn't work, then they apprently get to keep everything, including residual in the bank account.
Add to My Watchlist
What is My Watchlist?
 (20min delay)
|
|||||
|
Last
60.0¢ |
Change
0.000(0.00%) |
Mkt cap ! $738.7M | |||
| Open | High | Low | Value | Volume |
| 0.0¢ | 0.0¢ | 0.0¢ | $0 | 0 |
| OPT (ASX) Chart |
Day chart unavailable